Climb Bio, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
CLYM$11.74+6.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(29,447) | $(56,586) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 3,035 | 977 |
| Non-cash operating lease expense | 88 | 178 |
| Accretion of discounts on marketable securities, net | (1,240) | (63) |
| Depreciation and amortization expense | 38 | — |
| In-process research and development, related party | — | 51,659 |
| Unrealized foreign currency transaction loss | 24 | 9 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 1,272 | 2,425 |
| Other long-term assets | (1,352) | 15 |
| Accounts payable | 165 | (1,160) |
| Accounts payable and accrued liabilities, related party | — | 5 |
| Accrued expenses and other current liabilities | 944 | 326 |
| Operating lease liabilities | (109) | (249) |
| Long-term liabilities | — | (22) |
| Net cash used in operating activities | (26,582) | (2,486) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (77) | — |
| Purchases of marketable securities | (79,370) | — |
| Maturities of marketable securities | 41,482 | 13,751 |
| Issuance of promissory loan in connection with asset acquisition | — | (5,000) |
| Cash paid in connection with asset acquisition, net of cash received | — | (4,645) |
| Net cash provided by (used in) investing activities | (37,965) | 4,106 |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | — | 8,667 |
| Proceeds from issuance of common stock in private placement, net of issuance costs | — | 119,750 |
| Net cash provided by financing activities | — | 128,417 |
| Effect of exchange rate changes on cash and cash equivalents | — | (9) |
| Net change in cash and cash equivalents | (64,547) | 130,028 |
| Cash and cash equivalents at beginning of period | 87,229 | 93,112 |
| Cash and cash equivalents at end of period | $22,682 | $223,140 |
| Supplemental disclosure of cash flow information: | ||
| Operating lease liabilities arising from obtaining right-of-use assets | $216 | $— |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities | $76 | $— |
| Issuance of common stock in exchange for in-process research and development | $— | $41,867 |
| Settlement of promissory loan in connection with asset acquisition | $— | $5,036 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.